The Efficacy of Trimethoprim in Wound Healing of Patients with Epidermolysis Bullosa: A Randomized, Double Blinded, Placebo Controlled, Cross-over, Pilot Study
Year: 2009
Type: dissertation
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Hypothesis: Trimethoprim promotes wound healing, decreases lesion counts and improves quality of life of recessive dystrophic epidermolysis bullosa (RDEB) patients.\n\nObjectives: Assess feasibility of conducting a large randomized clinical trial. Determine efficacy of trimethoprim in healing of chronic wounds, decreasing lesion counts and improving quality of life of RDEB patients. \n\nMethods: Prospective, randomized, double-blinded, placebo-controlled, cross-over pilot study. \n\nResults: Ten patients enrolled in the trial, 7 completed both study periods. Despite showing that all patients improved on trimethoprim and that there was a 41% difference in affected area percent change favoring trimethoprim, the cross-over analysis did not show a significant difference between the drug and placebo (p=0.08). Secondary outcome measures did not achieve statistical significance.\n\nLimitations: Small sample size, large variation in wound size and unaccounted confounders.\n\nConclusions: Although patients experienced improvement while on trimethoprim, no statistical significant change was showed when compared to placebo.
Source: TSpace (University of Toronto)
Author: Irene Lara‐Corrales
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2725998942